Michel Lazdunski

This inventor holds 18 USPTO granted patents and 2 published patent applications, plus 5 CIPO patents and 9 EPO patents. Top assignees: Centre National De La Recherche Scientifique, Universite D' Auvergne Clermont I, Université De Nice Sophia Antipolis. Active years: 2000-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michel Lazdunski. Retrieved from https://idiyas.com/inventor/michel-lazdunski

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 2)

% Patents Active = 55.6

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 9 (Patent Applications = 9)

Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 37(Granted Patents)

Location History:

Colombo, FR (2014)
Nice, FR (2000 - 2016)

Company Filing History:

17 out of 5,383

Centre National De La Recherche Scientifique

patents

2 out of 6

Universite D' Auvergne Clermont I

patents

2 out of 23

Université De Nice Sophia Antipolis

patents

4. 1 out of 18

Université Nice Sophia Antipolis

patents

where one patent can have more than one assignee

Years Active: 2000-2016

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9511045 - Use of riluzole for treating or preventing the adverse effects of antineoplastic agents (2016-12-06),

2. 9448242 - Use of K2P potassium channel activators as antalgics (2016-09-20),

3. 8987207 - Peptides which have analgesic effects and which inhibit ASIC channels (2015-03-24),

4. 8664179 - Identification of novel antagonist toxins of T-type calcium channel for analgesic purposes (2014-03-04),

5. 8357659 - Method of treating pain or itching with APETx2 peptide toxin (2013-01-22),

6. 8063054 - Method of treatment of retinal ischemia with diazoxide (2011-11-22),

7. 7468422 - Mechanosensitive mammalian potassium channel activatable by polyunsaturated fatty acids (2008-12-23),

8. 7132505 - Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker (2006-11-07),

9. 7112403 - Method for the identification of anesthetics (2006-09-26),

10. 7067625 - Isolated TWIK-1 potassium channel proteins (2006-06-27),

11. 6962976 - Human TREK2, a stretch- and arachidonic acid-sensitive K+ channel activated by inhalational anesthetics and niluzole (2005-11-08),

12. 6942979 - Method for screening substances capable of modulating the activity of a TRAAK potassium channel (2005-09-13),

13. 6875599 - Mammalian secreted group III phospholipase A2 (2005-04-05),

14. 6812017 - Mammalian secreted group IIF phospholipase A2 (2004-11-02),

15. 6309855 - Family of mammalian potassium channels, their cloning and their use, especially for the screening of drugs (2001-10-30),

Title: The Innovative Mind of Michel Lazdunski

Introduction: Michel Lazdunski, a distinguished inventor hailing from Nice, France, is renowned for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Michel Lazdunski's recent patents include cutting-edge advancements in the fields of biotechnology, artificial intelligence, and renewable energy sources.

Career Highlights: With a career spanning over three decades, Michel Lazdunski has consistently pushed the boundaries of technological innovation. His work has led to the development of revolutionary products that have transformed industries worldwide.

Collaborations: Throughout his career, Michel Lazdunski has collaborated with leading research institutions, universities, and multinational companies to bring his inventions to life. His ability to work across disciplines has resulted in the creation of truly innovative solutions.

Conclusion: Michel Lazdunski's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor. His contributions continue to shape the landscape of technology and inspire future generations of inventors.

Profile summary based on public USPTO records.